Ke Cong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ke Cong has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Min Peng
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, USA
3 shared publications- Sharon B. Cantor
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
3 shared publications Jennifer Calvo
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, USA
2 shared publicationsAlessandro Vindigni
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
1 shared publicationAngela M. Zaino
Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT 06269, USA
1 shared publication- Arnab Ray Chaudhuri
Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 23 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
The effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in creating single-stranded DNA gaps and inducing sensitivity requires the FANCJ DNA helicase. Yet, how FANCJ relates to PARP1 inhibition or trapping, which contribute to PARPi toxicity, remains unclear. Here, we find PARPi effectiveness hinges on S-phase PARP1 activity, which is reduced in FANCJ deficient cells as G-quadruplexes sequester PARP1 and MSH2. Additionally, loss of the FANCJ-MLH1 interaction diminishes PARP1 activity; however, depleting MSH2 reinstates PARPi sensitivity and gaps. Indicating sequestered and trapped PARP1 are distinct, FANCJ loss increases PARPi resistance in cells susceptible to PARP1 trapping. However, with BRCA1 deficiency, the loss of FANCJ mirrors PARP1 loss or inhibition, with the detrimental commonality being loss of S-phase PARP1 activity. These insights underline the crucial role of PARP1 activity during DNA replication in BRCA1 deficient cells and emphasize the importance of understanding drug mechanisms for enhancing therapeutic response.
- 23 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessFANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
The effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in creating single-stranded DNA gaps and inducing sensitivity requires the FANCJ DNA helicase. Yet, how FANCJ relates to PARP1 inhibition or trapping, which contribute to PARPi toxicity, remains unclear. Here, we find PARPi effectiveness hinges on S-phase PARP1 activity, which is reduced in FANCJ deficient cells as G-quadruplexes sequester PARP1 and MSH2. Additionally, loss of the FANCJ-MLH1 interaction diminishes PARP1 activity; however, depleting MSH2 reinstates PARPi sensitivity and gaps. Indicating sequestered and trapped PARP1 are distinct, FANCJ loss increases PARPi resistance in cells susceptible to PARP1 trapping. However, with BRCA1 deficiency, the loss of FANCJ mirrors PARP1 loss or inhibition, with the detrimental commonality being loss of S-phase PARP1 activity. These insights underline the crucial role of PARP1 activity during DNA replication in BRCA1 deficient cells and emphasize the importance of understanding drug mechanisms for enhancing therapeutic response.
- 22 September 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (22) , 4692-4708.e9
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps
- 22 September 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (22) , 4692-4708.e9
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps
- Open Access
- 12 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (24) , eaaz7808
Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability
Translesion synthesis is a cancer adaptation that suppresses replication stress–induced gaps that limit fitness.
- 12 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (24) , eaaz7808
Open AccessInhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability
Translesion synthesis is a cancer adaptation that suppresses replication stress–induced gaps that limit fitness.
- Open Access
- 1 September 2018
- Published by Elsevier in Cell Reports
- Vol. 24 (12) , 3251-3261
Opposing Roles of FANCJ and HLTF Protect Forks and Restrain Replication during Stress
- 1 September 2018
- Published by Elsevier in Cell Reports
- Vol. 24 (12) , 3251-3261
Open AccessOpposing Roles of FANCJ and HLTF Protect Forks and Restrain Replication during Stress